CGEM Stock Summary and Trading Ideas (Cullinan Therapeutics | NASDAQ:CGEM)

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

What symbol and exchange does Cullinan Therapeutics shares trade?

Cullinan Therapeutics trades on the NASDAQ stock market under the symbol CGEM.

What is Cullinan Therapeutics stock price doing today?

As of June 12, 2026, CGEM stock price climbed to $13.70 with 1,270,384 million shares trading.

What is Cullinan Therapeutics's Beta?

CGEM has a beta of 1.52, meaning it tends to be more sensitive to market movements. CGEM has a correlation of 0.06 to the broad based SPY ETF.

How much is Cullinan Therapeutics worth?

CGEM has a market cap of $841.88 million. This is considered a Small Cap stock.

How much money does Cullinan Therapeutics make?

Last quarter Cullinan Therapeutics reported $0 in Revenue and -$.75 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.09.

What is the highest and lowest price Cullinan Therapeutics traded in the last 3 year period?

In the last 3 years, CGEM traded as high as $30.19 and as low as $5.68.

What are the top ETFs holding Cullinan Therapeutics?

The top ETF exchange traded funds that CGEM belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.

Is Cullinan Therapeutics (CGEM) a good investment?

CGEM has outperformed the market in the last year with a return of +53.1%, while the SPY ETF gained +24.1%. However, in the most recent history, CGEM shares have underperformed the stock market with its stock returning -1.8% in the last 3 month period and -16.7% for the last 2 week period, while SPY has returned +11.6% and -1.9%, respectively.

What are the support and resistance levels for Cullinan Therapeutics (CGEM)?

CGEM support price is $12.26 and resistance is $13.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEM shares will trade within this expected range on the day.